Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

In the first quarter of fiscal 2008, the Company recorded comprehensive income of $16,000 and accumulated other comprehensive income totaling $148,000. The total amount of $164,000 represents an adjustment to fair value of available-for-sale financial instruments, which in this case, represent shares in Orchid Cellmark Inc., a Nasdaq listed company.

CASH FLOW

Operating activities

Net loss from operations totaled $1,644,000 in the first quarter of fiscal 2008 (2007 - $1,342,000) for an increase of $302,000. Excluding non-cash and working capital items, the cash used in the first quarter of fiscal 2008 totaled $1,836,000 (2007 - $1,602,000) and represents an increase of $234,000.

Financing activities

Financing activities in the first quarter of fiscal 2008 were nil (2007 - $6,480,000). In the first quarter of fiscal 2007, the Company completed a private placement with net proceeds of $6,480,000.

Investing activities

Investing activities in the first quarter of fiscal 2008 used cash of $50,000 while in the first quarter of fiscal 2007 investing activities provided a source of cash totaling $6,625,000. The majority of the reduction in investing activities reflects the redemption of $6,640,000 in short term investments in the first quarter of fiscal 2007. Capital purchases were negligible in both the first quarters of fiscal 2008 and 2007 totaling $50,000 and $15,000, respectively.

LIQUIDITY AND CAPITAL RESOURCES

Since inception, the Company has financed its operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the C
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the leading ... 2nd generation cell therapy POD® design. The 2nd generation portfolio not only delivers ... new POD® design. , “G-CON first offered our miniPOD CT product line ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... Aug. 24 Advanced Instruments has introduced a next-generation Web ... purchasing osmometers, cryoscopes, and microbiological laboratory instruments. The site, ... , was developed from the perspective of the Web ... scientific materials, and technical support. , , ...
... , BASKING RIDGE, N.J., Aug. 24 ... the development of antithrombotic therapeutic aptamers with active control ... the first Phase I study of a subcutaneous administration ... a double-blind, randomized, placebo-controlled, single ascending dose study to ...
... , SAN DIEGO, Aug. 24 ... announced that Mark Booth has joined the Company as Chief ... commercial and business development experience to Orexigen. Most recently ... where he presided over the commercial, medical and scientific affairs, ...
Cached Biology Technology:Advanced Instruments Introduces Next-Generation Web Site 2Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System 2Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer 2
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... A scientific project funded by the BBVA Foundation and conducted ... (CSIC) explored around 100 kilometers of practically uncharted Atlantic beach ... the years 2006 and 2007. In the course of their ... hope for the survival of the leatherback turtle. This species ...
... , Now that Olympia is approaching, the Chinese authorities ... large cities with different measures. For example, the car ... ordered not to use 70 percent of all company ... even or odd days - in accordance with their ...
... A new study by researchers at The University of Texas ... to continue the current practice of retesting women during their ... tested positive for the infection previously. Group B Streptococcus, ... harmless to carriers but in some cases can be deadly ...
Cached Biology News:GKSS membranes reduce air pollution in Beijing 2Recurrence of group B strep high in subsequent pregnancies, say UT Houston obstetricians 2
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: